Atormac
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 258  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  
 Resource Links
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (470 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this Article
   References

 Article Access Statistics
    Viewed1018    
    Printed15    
    Emailed0    
    PDF Downloaded24    
    Comments [Add]    

Recommend this journal

 


 
Table of Contents    
CORRESPONDENCE
Year : 2017  |  Volume : 65  |  Issue : 4  |  Page : 921-922

Author's Reply: Choice of antiepileptic drugs in the treatment of tumor-related epilepsy


1 Department of Neurosurgery, Oncology, Wayne State University School of Medicine, Comprehensive Epilepsy Center, Detroit Medical Center and Wayne State University, Multidisciplinary Neuro-Oncology Program, Karmanos Cancer Institute, Detroit, Michigan, USA
2 Department of Neurology, Wayne State University School of Medicine, Comprehensive Epilepsy Center, Detroit Medical Center and Wayne State University, Detroit, Michigan, USA

Date of Web Publication5-Jul-2017

Correspondence Address:
Sandeep Mittal
Department of Neurosurgery, Wayne State University, 4160 John R Street, Suite 930, Detroit, Michigan - 48201
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/neuroindia.NI_541_17

Rights and Permissions



How to cite this article:
Mittal S, Shah AK. Author's Reply: Choice of antiepileptic drugs in the treatment of tumor-related epilepsy. Neurol India 2017;65:921-2

How to cite this URL:
Mittal S, Shah AK. Author's Reply: Choice of antiepileptic drugs in the treatment of tumor-related epilepsy. Neurol India [serial online] 2017 [cited 2019 Dec 5];65:921-2. Available from: http://www.neurologyindia.com/text.asp?2017/65/4/921/209528




Sir,

We truly appreciate and welcome the question raised regarding the choice of antiepileptic drugs (AEDs) in the treatment of tumor-related epilepsy (TRE). As you have pointed out, there is no strong evidence supported by prospective randomized clinical trials to indicate that the choice of one AED is superior in patients with TRE. In the absence of well-controlled randomized trials, the decision on choice of AED that provides the best risk–benefit ratio is somewhat arbitrary and based mainly on the treating physician's preference and experience.

As we have mentioned in our article,[1] several studies have shown that the pharmacokinetic and pharmacodynamics interactions between the AEDs and medications commonly used in patients with brain tumors render enzyme-inducing AEDs less desirable as they may reduce the efficacy of many chemotherapeutic agents.[2] The newer AEDs are generally associated with fewer side effects and are typically better tolerated in patients with TRE, who often have impaired neurological function at baseline.[3] Due to these reasons, newer AEDs are preferred for treatment in patients with TRE in North America and Europe.



 
  References Top

1.
Klinger NV, Shah AK, Mittal S. Management of brain tumor-related epilepsy. Neurol India 2017;65:60-70.  Back to cited text no. 1
[PUBMED]  [Full text]  
2.
Rogers LR. Chemotherapy and immunotherapy of brain tumors: What the epileptologist must know. Epilepsia 2013;4(Suppl 9):105-8.  Back to cited text no. 2
    
3.
Perucca E. Optimizing antiepileptic drug treatment in tumoral epilepsy. Epilepsia 2013;54(Suppl 9):97-104.  Back to cited text no. 3
[PUBMED]    




 

Top
Print this article  Email this article
   
Online since 20th March '04
Published by Wolters Kluwer - Medknow